Karvellas Constantine J, Pink Fred, McPhail Mark, Cross Timothy, Auzinger Georg, Bernal William, Sizer Elizabeth, Kutsogiannis Demetrios J, Eltringham Ian, Wendon Julia A
Division of Critical Care Medicine, University of Alberta, 3C1.16 Walter C. Mackenzie Centre, 8440-112th Street, Edmonton, AB T6G 2B7, Canada.
Intensive Care Med. 2009 Aug;35(8):1390-6. doi: 10.1007/s00134-009-1472-x. Epub 2009 Apr 3.
To determine what physiological and biochemical factors predict development of bacteraemia and mortality in patients with acute liver failure (ALF).
Retrospective analysis of 206 ALF patients admitted to a specialist liver intensive therapy unit (LITU) from January 2003 to July 2005 (data collected prospectively).
A total of 206 patients were defined with ALF: 72 (35%) suffered bacteraemia (BAClf) and 134 (65%) did not (NBAClf). Gram positive organisms were observed in 44% of isolates, gram negatives in 52% and fungaemia in 4%. Median time to first bacteraemia was 10 (7-16) days. On admission, BAClf patients had higher SIRS scores and degrees of hepatic encephalopathy (HE). During their LITU course, BAClf patients had significantly increased requirements for renal replacement therapy (RRT), mechanical ventilation, and longer median LITU stay. Multivariate analysis (logistical regression) demonstrated significant predictors of bacteraemia on admission were HE grade >2 (Odds Ratio 1.6) and SIRS score >1 (OR 2.7). In all patients, independent predictors of mortality (logistical) were age (OR 1.41), maximum HE grade pre-intubation (1.76), Lactate (1.14) and Acute Physiology and Chronic Health Evaluation II score (APACHEII) (1.09), but not bacteraemia. Transplantation was protective (OR 0.20).
In this study, severity of hepatic encephalopathy and SIRS score >1 were predictive of bacteraemia. APACHEII was independently predictive of mortality in all ALF patients but not bacteraemia.
确定哪些生理和生化因素可预测急性肝衰竭(ALF)患者发生菌血症及死亡情况。
对2003年1月至2005年7月入住某专科肝脏重症治疗病房(LITU)的206例ALF患者进行回顾性分析(数据为前瞻性收集)。
共206例患者被确诊为ALF:72例(35%)发生菌血症(BAClf),134例(65%)未发生(NBAClf)。分离出的菌株中44%为革兰氏阳性菌,52%为革兰氏阴性菌,4%为真菌血症。首次发生菌血症的中位时间为10(7 - 16)天。入院时,BAClf患者的全身炎症反应综合征(SIRS)评分及肝性脑病(HE)程度更高。在其LITU治疗过程中,BAClf患者对肾脏替代治疗(RRT)、机械通气的需求显著增加,且在LITU的中位住院时间更长。多因素分析(逻辑回归)显示,入院时菌血症的显著预测因素为HE分级>2(比值比1.6)及SIRS评分>1(OR 2.7)。在所有患者中,死亡的独立预测因素(逻辑分析)为年龄(OR 1.41)、插管前最高HE分级(1.76)、乳酸(1.14)及急性生理与慢性健康状况评估II评分(APACHEII)(1.09),但不包括菌血症。肝移植具有保护作用(OR 0.20)。
在本研究中,肝性脑病的严重程度及SIRS评分>1可预测菌血症。APACHEII可独立预测所有ALF患者的死亡情况,但不能预测菌血症。